Lisinopril, losartan, and atorvastatin ( DrugBank: Losartan, Lisinopril, Atorvastatin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 222 | Primary nephrotic syndrome | 1 |
222. Primary nephrotic syndrome
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00814255 (ClinicalTrials.gov) | December 2008 | 22/12/2008 | Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial | Novel Therapies for Resistant Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Drug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactose | New York University School of Medicine | University of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 1 Year | 65 Years | All | 32 | Phase 2 | United States;Canada |